Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients-Reference-Cited by-同舟云学术

Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients

Published:2009-04 Issue:2 Volume:29 Page:165-169
ISSN:0271-0749
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Henderson David C.,Fan Xiaoduo,Copeland Paul M.,Sharma Bikash,Borba Christina P.,Boxill Ryan,Freudenreich Oliver,Cather Corinne,Evins A. Eden,Goff Donald C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference44 articles.

1. Safety of olanzapine.;Beasley;J Clin Psychiatry,1997

2. Olanzapine increases weight and serum triglyceride levels.;Osser;J Clin Psychiatry,1999

3. Olanzapine: weight gain and therapeutic efficacy.;Gupta;J Clin Psychopharmacol,1999

4. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study.;Henderson;Am J Psychiatry,2000

5. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.;Koro;Arch Gen Psychiatry,2002

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects;Asian Journal of Psychiatry;2024-10

2. Long-term Metabolic Side Effects of Second-Generation Antipsychotics in Chinese Patients with Schizophrenia: A Within-Subject Approach with modelling of dosage effects;2024-03-04

3. Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study;Psikhiatriya;2023-06-19

4. A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease;Life Sciences;2023-02

5. Partial agonists of dopamine receptors: clinical effects and dopamine receptor interactions in combining aripiprazole with a full antagonist in treating psychosis;BJPsych Advances;2023-01-27